Back to top
more

Regeneron Pharmaceuticals (REGN)

(Delayed Data from NSDQ)

$903.00 USD

903.00
79,353

+6.18 (0.69%)

Updated Apr 22, 2024 11:55 AM ET

After-Market: $899.71 -3.29 (-0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for REGN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Regeneron Pharmaceuticals, Inc. [REGN]

Reports for Purchase

Showing records 101 - 120 ( 589 total )

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 101

01/31/2022

Daily Note

Pages: 3

CHMP to Decide on Expanding Dupixent Approval in Asthmatic Children Aged 6 to 11; Reiterate Buy and $843 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 102

01/28/2022

Company Report

Pages: 5

Regeneron Voluntarily Withdraws sBLA for Libtayo in 2L Cervical Cancer

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 103

01/26/2022

Daily Note

Pages: 7

Libtayo’s Dominance in Dermato-Oncology Unlikely To Be Perturbed by New Entrants, in Our View

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 104

01/25/2022

Industry Report

Pages: 11

Rx for Portfolios, Part 1: Companies With Transformative Clinical Readouts Fast Approaching

Provider: H.C. Wainwright & Co., Inc.

Analyst: TSAO D

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 105

01/21/2022

Company Report

Pages: 24

Comprehensive Technical and Fundamental Analysis for REGN.

Provider: Stock Traders Daily

Analyst: Research Department

Price: 35.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 106

01/19/2022

Daily Note

Pages: 4

PDUFA Date Set For Libtayo-Chemo in 1L NSCLC and Dupixent Improves Prurigo Nodularis; Reiterate Buy and $844 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 107

01/11/2022

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 108

01/10/2022

Daily Note

Pages: 7

Eylea and REGEN-COV Annual Sales Beat Our Estimates; We Remain Bullish on Regeneron

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 109

01/10/2022

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 110

12/22/2021

Daily Note

Pages: 4

ALNY-REGN Seek MHRA Approval in the UK to Initiate a Phase 1 Trial for ALNY-APP in AD and CAA; Reiterate Buy and $844 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 111

12/16/2021

Daily Note

Pages: 3

Regeneron’s Next-Gen SARS-CoV-2 Antibodies Active Against Omicron and Delta; Set for Clinic in 1Q22

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 112

12/14/2021

Daily Note

Pages: 11

Regeneron Provides Post-ASH Clinical Development Strategy Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 113

12/13/2021

Daily Note

Pages: 3

Regeneron Presents Positive Results for Phase 1 Study of REGN5458 in Relapsed or Refractory Multiple Myeloma

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 114

12/10/2021

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 115

12/08/2021

Daily Note

Pages: 3

NICE Backs Dupixent as Add-On Therapy Option for Severe Asthma in Patients Ages 12+; Reiterate Buy and $844 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 5.00

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 116

11/30/2021

Daily Note

Pages: 6

Oh My Oh My Omicron: Does the Latest Variant Spell the End of REGEN-COV?

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 117

11/24/2021

Daily Note

Pages: 6

Recent Developments Reaffirm Our Enthusiasm for Regeneron; Reiterate Buy Rating and $844 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 118

11/22/2021

Daily Note

Pages: 8

R&D Day Reveal; Alnylam-Regeneron Partner in ALS and Glaucoma; Reiterate Buy and $844 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 119

11/11/2021

Company Report

Pages: 10

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: Regeneron Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 120

11/05/2021

Company Report

Pages: 9

The Triumvirate of Dupixent, Eylea and REGEN-COV Drive 3Q2021 Revenue and EPS Beat; Reiterate Buy; Raise PT to $844

Provider: H.C. Wainwright & Co., Inc.

Analyst: KING M

Price: 12.50

Research Provided by a Third Party